<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04694976</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0885</org_study_id>
    <secondary_id>ID-RCB</secondary_id>
    <nct_id>NCT04694976</nct_id>
  </id_info>
  <brief_title>Vitamin D Status in Children With Sickle Cell Disease Living in Lyon, France</brief_title>
  <acronym>EVADDREP</acronym>
  <official_title>Evaluation of Vitamin D Deficiency Distribution in Children With Sickle Cell Disease Followed in Lyon, France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D deficiency may be under-diagnosed in sickle cell disease French children.&#xD;
      Therefore, the investigator need an epidemiologic study about the prevalence of vitamin D&#xD;
      deficiency in this specific population. There are not specific guidelines neither testing nor&#xD;
      treatment. The investigator propose to test vitamin D status in all children with sickle cell&#xD;
      disease who are consulting their referring haematologist doctor or in the emergency ward.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of 25-OH Vitamin D level</measure>
    <time_frame>Day 1</time_frame>
    <description>We classify vitamin D status as follows :&#xD;
Sufficiency &gt; &gt;75nmol/L (&gt;30 ng/mL)&#xD;
Insufficiency 50-75 nmol/L (20-30 ng/mL)&#xD;
Deficiency 12-50nmol/L (5-20 ng/mL)&#xD;
Severe deficiency &lt;12 nmol/L (&lt;5 ng/mL)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Sickle cell disease children from Lyon, France</arm_group_label>
    <description>Sickle cell disease children, followed in IHOPe (Institut d'Hématologie et d'Oncologie Pédiatrique) center, consulting their referring haematologist doctor or in emergency ward, with prescribed blood sample.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>25-OH Vitamin D measure</intervention_name>
    <description>As a complement to the off-study prescription, the investigator are taking two 1 mL tubes of extra blood to measure vitamin D, calcium, phosphorus, parathyroid hormone (PTH) and creatinine.</description>
    <arm_group_label>Sickle cell disease children from Lyon, France</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will focus on minor patients (0-17 years) with sickle cell disease, currently&#xD;
        monitored in the active queue of the Lyon sickle cell reference centre of IHOPe, consulting&#xD;
        their referring physician or paediatric emergencies of HFME, and having a blood test&#xD;
        independently of the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children: under 18 years old&#xD;
&#xD;
          -  Sickle cell any genetic type homozygous or composite heterozygous&#xD;
&#xD;
          -  To receive an assessment independently of the study, during a presentation to the&#xD;
             emergency ward and/or a follow-up consultation by the hematologist&#xD;
&#xD;
          -  no parental opposition signed by at least one parent/legal representative and no child&#xD;
             opposition&#xD;
&#xD;
          -  social security beneficiary&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hematologic grafting&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie LAUNAY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Urgences pédiatriques de l'Hôpital Femme Mère Enfant - Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valérie LAUNAY, MD</last_name>
    <phone>04 27 85 62 13</phone>
    <phone_ext>+33</phone_ext>
    <email>valerie.launay@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Femme Mère enfant - Urgences pédiatriques</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Valérie LAUNAY, MD</last_name>
      <phone>04 27 85 62 13</phone>
      <phone_ext>+33</phone_ext>
      <email>valerie.launay@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Valérie LAUNAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D deficiency prevalence rate</keyword>
  <keyword>Vitamin D level</keyword>
  <keyword>Children with sickle cell disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

